Professional background

Dr Arne de Kreuk is a consultant haematologist specialising in haemoglobin disorders. He is primarily based at North Middlesex University Hospital and he is a member of the red cell team at UCLH. He provides specialist outreach clinics for patients with sickle cell disorder and thalassaemia in Cambridge, Norwich and Stevenage.

 He graduated with honours from the VU University Medical School in Amsterdam, the Netherlands, in 1997 and completed specialist training in 2008. In 2006 he was awarded a PhD for a thesis on the preservation of stem cells in autologous grafts. He has a special interest in quality improvement and has followed the IHI executive development programme for patient safety.

Research interests

Clinical trials in disease-modifying drugs in red cell disorders

Languages spoken



van de Ree-Pellikaan C, de Kreuk AM, Schaar CG, Beeker A, Dompeling EC, Gerrits CJH, van Houten AA, Schipperus MR, Strobbe L, Posthuma EFM, Klauke K, Westerweel PE. Treatment strategies for polycythemia vera: Observations in a Dutch "real-world" cohort study. Eur J Haematol. 2019 Nov;103(5):453-459.

 Kortekaas KA, de Kreuk AM, Jensch S, Wientjes CA, Veenstra J. Intestinal dilatation: do not forget a tropical origin. Neth J Med 2017;75(2):90-91.

 Regelink JC, Raijmakers PG, Bravenboer N, Milek R, Hoetjes NJ, de Kreuk AM, van Duin M, Wondergem MJ, Lips P, Sonneveld P, Zijlstra JM, Zweegman S. (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma. EJNMMI Res. 2016 Dec;6(1):46. doi: 10.1186/s13550-016-0197-4. Epub 2016 May 31.

Hamming LC, de Kreuk AM, Zweegman S. De kunst van het kijken; uw diagnose? Ned Tijdschr Hematol 2013;10:278-80.

 Porcelijn L, Huiskes E, Maatman R, de Kreuk AM, de Haas M. Acquired Glanzmann's thrombasthenia caused by glycoprotein IIb/IIIa autoantibodies of the immunoglobulin G1 (IgG1), IgG2 or IgG4 subclass: a study in six cases. Vox Sang. 2008;95:324-30.

 De Kreuk AM, Zevenbergen A, Jonuleit T, Schuurhuis GJ, Huijgens PC Hendriks EC, van Oostveen JW, Lemke HD, Jonkhoff AR. Preservation of G-CSF mobilized whole blood in an automated hollow fiber bioreactor system [letter]. Cytotherapy 2004;6:380-384.

 Jonkhoff AR, de Kreuk AM, Franschman G, van der Lelie J, Schuurhuis GJ, Dräger AM, Zweegman S, Huijgens PC, Ossenkoppele GJ. Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 x 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma. Br J Haematol. 2002;118:90-100.

 De Kreuk AM, Jonkhoff AR, Zevenbergen A, Wilhelm AJ, van Oostveen JW, Schuurhuis GJ, Huijgens PC. In-vitro safety profile of G-CSF-mobilized whole blood after storage for 7 days in an infusable-grade L15 medium. Transfusion 2002;42:433-442.

 De Kreuk AM, Zevenbergen A, van Oostveen JW, Schuurhuis GJ, Huijgens PC, Jonkhoff AR. A single-step colony-forming unit assay for unseparated mobilized peripheral blood, cord blood and bone marrow. J Hematother Stem Cell Res. 2001;10:795-806.

 De Kreuk AM, Jonkhoff AR, Zevenbergen A, Hendriks EC, Schuurhuis GJ, Ossenkoppele GJ, Dräger AM, van Oostveen JW, Huijgens PC. Storage of unprocessed G-CSF-mobilized whole blood in a modified Leibovitz's L15 medium preserves clonogenic capacity for at least 7 days. Bone Marrow Transplant. 2001;28:145-155.

 De Kreuk AM, van der Schoot JThM. Foetale sterfte en ernstige pre-eclampsie door onderliggend lijden. Tijdschr Verlosk 1997;22:30-35.

 De Kreuk AM, Ossenkoppele GJ, Meijer CJLM, Huijgens PC. Langere overleving door hogedosischemotherapie en autologe beenmergtransplantatie bij non-Hodgkin-lymfoom bij geselecteerde patiënten. Ned Tijdschr Geneeskd 1997;141:1614-1620.

 Ossenkoppele GJ, Schuurhuis GJ, Jonkhoff AR, Dräger AM, Westra G, Oberink JW, Legdeur MC, de Kreuk AM, Zweegman S, Huijgens PCl. G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma. Bone Marrow Transplantation. 1996;18:427-431.

 De Kreuk AM, Ossenkoppele GJ, Meijer CJLM, Huijgens PC. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant. 1996;17:963-971.